Nexalis Therapeutics Limited (ASX:NX1)

Nexalis Therapeutics Income Statement

Financials in millions AUD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Revenue	-	-	-	0.02	0.18
Other Revenue	0.77	0.4	1.2	-	-
Revenue	0.77	0.4	1.2	0.02	0.18
Revenue Growth (YoY)	91.06%	-66.63%	4755.02%	-86.35%	721.35%
Cost of Revenue	-	-	-	-	0.12
Gross Profit	0.77	0.4	1.2	0.02	0.07
Selling, General & Admin	0.67	1.02	1.08	0.89	0.99
Research & Development	1.76	0.62	1.45	0.98	0.12
Other Operating Expenses	0.02	0.02	0.04	0.08	0.07
Operating Expenses	2.46	1.68	2.63	1.98	1.18
Operating Income	-1.69	-1.28	-1.42	-1.95	-1.11
Interest Expense	-0.14	-0.09	-0.01	-	-
Interest & Investment Income	-	0	0	0.02	0
Other Non Operating Income (Expenses)	-	0.15	-	-	-
EBT Excluding Unusual Items	-1.83	-1.21	-1.43	-1.94	-1.11
Gain (Loss) on Sale of Assets	-	-	-	0.01	-
Asset Writedown	-	-	-0.01	-	-
Pretax Income	-1.83	-1.21	-1.44	-1.93	-1.11
Earnings From Continuing Operations	-1.83	-1.21	-1.44	-1.93	-1.11
Net Income	-1.83	-1.21	-1.44	-1.93	-1.11
Net Income to Common	-1.83	-1.21	-1.44	-1.93	-1.11
Shares Outstanding (Basic)	216	213	189	173	168
Shares Outstanding (Diluted)	216	213	189	173	168
Shares Change (YoY)	1.06%	12.72%	9.42%	3.27%	68.94%
EPS (Basic)	-0.01	-0.01	-0.01	-0.01	-0.01
EPS (Diluted)	-0.01	-0.01	-0.01	-0.01	-0.01
Free Cash Flow	-0.89	-0.37	-1.96	-1.85	-1.16
Free Cash Flow Per Share	-0.00	-0.00	-0.01	-0.01	-0.01
Gross Margin	100.00%	100.00%	100.00%	100.00%	36.59%
Operating Margin	-220.50%	-318.39%	-118.22%	-7879.43%	-611.57%
Profit Margin	-238.28%	-300.98%	-119.87%	-7770.36%	-611.38%
Free Cash Flow Margin	-115.69%	-91.78%	-162.94%	-7444.75%	-638.32%
EBITDA	-	-	-1.41	-1.94	-1.11
EBITDA Margin	-	-	-117.42%	-	-
D&A For EBITDA	-	-	0.01	0.01	0
EBIT	-1.69	-1.28	-1.42	-1.95	-1.11
EBIT Margin	-220.50%	-	-118.22%	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.